Hoth Therapeutics
We are committed to the patient experience by following the science to develop impactful and versatile treatment solutions for everyone. At HOTH, we stand by our mission to innovate today for a better tomorrow.
Learn more about our therapeutic areas, Early Access program, as well as ongoing and future clinical trial opportunities.
If you have questions regarding our clinical trials, please contact us here.
Current Development
HT-ALZ
Alzheimer’s Disease
HT-ALZ is being developed for the treatment of Alzheimer’s disease and associated symptoms (eg, dementia). Its active pharmaceutical ingredient is an already approved drug, making HT-ALZ eligible for development via the 505(b)(2) regulatory pathway relying on existing safety data. HT-ALZ is being developed as an oral soluble film formulation for easy patient dosing and differentiation from existing products. Data from preclinical studies shows a significant decrease in Aβ in both male and female APP/PS1+/- mice after acute treatment with HT-ALZ, compared to placebo-treated animals and baseline Aβ levels.